SAFETY DATA SHEET

Furosemide Solid Formulation

Version 2.7  Revision Date: 10.10.2020  SDS Number: 645631-00010  Date of last issue: 23.03.2020
Date of first issue: 03.05.2016

Section 1: Identification

Product name: Furosemide Solid Formulation

Manufacturer or supplier’s details
Company: MSD
Address: 33 Whakatiki Street - Private Bag 908
         Upper Hutt - New Zealand
Telephone: 908-740-4000
Emergency telephone number: 1-908-423-6000
E-mail address: EHSDATASTEWARD@msd.com
Telefax: 908-735-1496

Recommended use of the chemical and restrictions on use
Recommended use: Veterinary product

Section 2: Hazard identification

GHS Classification
Specific target organ toxicity - repeated exposure: Category 1 (Kidney, Liver)

GHS label elements
Hazard pictograms: □ □
Signal word: Danger
Hazard statements: H372 Causes damage to organs (Kidney, Liver) through prolonged or repeated exposure.
Precautionary statements: Prevention:
P260 Do not breathe dust.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
Response:
P314 Get medical advice/attention if you feel unwell.
Disposal:
P501 Dispose of contents/container to an approved waste disposal plant.
SAFETY DATA SHEET

Furosemide Solid Formulation

Other hazards which do not result in classification
Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

Section 3: Composition/information on ingredients

<table>
<thead>
<tr>
<th>Substance / Mixture</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Starch</td>
<td>9005-25-8</td>
<td>&gt;= 30 -&lt; 60</td>
</tr>
<tr>
<td>Furosemide</td>
<td>54-31-9</td>
<td>&gt;= 10 -&lt; 30</td>
</tr>
<tr>
<td>Cellulose</td>
<td>9004-34-6</td>
<td>&lt; 10</td>
</tr>
</tbody>
</table>

Section 4: First-aid measures

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled: If inhaled, remove to fresh air. Get medical attention if symptoms occur.

In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water. Get medical attention if symptoms occur.

In case of eye contact: If in eyes, rinse well with water. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed: Causes damage to organs through prolonged or repeated exposure. Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician: Treat symptomatically and supportively.

Section 5: Fire-fighting measures

Suitable extinguishing media: Water spray
                   Alcohol-resistant foam
                   Carbon dioxide (CO2)
                   Dry chemical

Unsuitable extinguishing media: None known.

Specific hazards during firefighting: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Section 6: Accidental release measures

Personal precautions, protective equipment and emergency procedures:
- Use personal protective equipment.
- Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions:
- Avoid release to the environment.
- Prevent further leakage or spillage if safe to do so.
- Retain and dispose of contaminated wash water.
- Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up:
- Sweep up or vacuum up spillage and collect in suitable container for disposal.
- Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
- Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
- Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
- Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

Section 7: Handling and storage

Technical measures:
- Static electricity may accumulate and ignite suspended dust causing an explosion.
- Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation:
- Use only with adequate ventilation.

Advice on safe handling:
- Do not breathe dust.
- Do not swallow.
- Avoid contact with eyes.
- Avoid prolonged or repeated contact with skin.
- Wash skin thoroughly after handling.
- Handle in accordance with good industrial hygiene and safety practices.
practice, based on the results of the workplace exposure assessment
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures
If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Conditions for safe storage
Keep in properly labelled containers.
Store in accordance with the particular national regulations.

Materials to avoid
Do not store with the following product types:
Strong oxidizing agents

Section 8: Exposure controls/personal protection

Components with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Starch</td>
<td>9005-25-8</td>
<td>WES-TWA</td>
<td>10 mg/m³</td>
<td>NZ OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td>Furosemide</td>
<td>54-31-9</td>
<td>TWA</td>
<td>200 µg/m³</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA</td>
<td>OEB 2 (&gt;=100 - 1000 ug/m³)</td>
<td>Internal</td>
</tr>
<tr>
<td>Cellulose</td>
<td>9004-34-6</td>
<td>WES-TWA</td>
<td>10 mg/m³</td>
<td>NZ OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
</tbody>
</table>

Engineering measures
Use feasible engineering controls to minimize exposure to compound.
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment
Respiratory protection
If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type
Particulates type

Hand protection
Material
Chemical-resistant gloves

Eye protection
Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection: Work uniform or laboratory coat.

Section 9: Physical and chemical properties

Appearance: powder
Color: yellow
Odour: No data available
Odour Threshold: No data available
pH: No data available
Melting point/freezing point: No data available
Initial boiling point and boiling range: No data available
Flash point: Not applicable
Evaporation rate: No data available
Flammability (solid, gas): May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids): No data available
Upper explosion limit / Upper flammability limit: No data available
Lower explosion limit / Lower flammability limit: No data available
Vapour pressure: No data available
Relative vapour density: No data available
Relative density: No data available
Density: No data available
Solubility(ies)
  Water solubility: No data available
Partition coefficient: n-octanol/water: No data available
Auto-ignition temperature: No data available
Decomposition temperature: No data available
SAFETY DATA SHEET

Furosemide Solid Formulation

Viscosity
    Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : Not applicable

Particle size : No data available

---

Section 10: Stability and reactivity

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions
    May form explosive dust-air mixture during processing, handling or other means.
    Can react with strong oxidizing agents.

Conditions to avoid
    Heat, flames and sparks.
    Avoid dust formation.

Incompatible materials
    Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

---

Section 11: Toxicological information

Exposure routes
    Inhalation
    Skin contact
    Ingestion
    Eye contact

Acute toxicity
Not classified based on available information.

Components:

Starch:
    Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Furosemide:
    Acute oral toxicity : LD50 (Rat): 2,600 mg/kg
    LD50 (Dog): 2,000 mg/kg
    LD50 (Rabbit): 800 mg/kg

Acute toxicity (other routes of administration) : LD0 (Humans): 6 - 29 mg/kg
    Application Route: Intravenous
SAFETY DATA SHEET

Furosemide Solid Formulation

Version 2.7  Revision Date: 10.10.2020  SDS Number: 645631-00010  Date of last issue: 23.03.2020

Date of first issue: 03.05.2016

LD50 (Rat): 800 mg/kg
Application Route: Intravenous

Cellulose:
Acute oral toxicity  :  LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity  :  LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity  :  LD50 (Rabbit): > 2,000 mg/kg

Skin corrosion/irritation
Not classified based on available information.

Serious eye damage/eye irritation
Not classified based on available information.

Components:

Starch:
Species  :  Rabbit
Result  :  No eye irritation

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Components:

Starch:
Test Type  :  Maximisation Test
Exposure routes  :  Skin contact
Species  :  Guinea pig
Result  :  negative

Chronic toxicity

Germ cell mutagenicity
Not classified based on available information.

Components:

Starch:
Genotoxicity in vitro  :  Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Furosemide:
Genotoxicity in vitro  :  Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Test system: mouse lymphoma cells
Result: positive

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Test system: mammalian liver cells
Result: negative

Test Type: Chromosome aberration test in vitro
Test system: Chinese hamster ovary cells
Result: positive

Test Type: In vitro sister chromatid exchange assay in mammalian cells
Test system: Chinese hamster cells
Result: negative

Genotoxicity in vivo:
Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Result: negative

Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Chinese hamster
Application Route: Ingestion
Result: negative

Cellulose:
Genotoxicity in vitro:
Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Genotoxicity in vivo:
Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Result: negative

Carcinogenicity:
Not classified based on available information.

Components:
Furosemide:
Species: Rat
Application Route: Ingestion
Exposure time: 104 weeks
SAFETY DATA SHEET

Furosemide Solid Formulation

Version 2.7  Revision Date: 10.10.2020  SDS Number: 645631-00010  Date of last issue: 23.03.2020  Date of first issue: 03.05.2016

<table>
<thead>
<tr>
<th>LOAEL</th>
<th>Result</th>
<th>Species</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>LOAEL</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>16 mg/kg body weight</td>
<td>equivocal</td>
<td>Mouse</td>
<td>Ingestion</td>
<td>2 Years</td>
<td>91 mg/kg body weight</td>
<td>positive</td>
</tr>
</tbody>
</table>

**Cellulose:**

<table>
<thead>
<tr>
<th>Species</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>Ingestion</td>
<td>72 weeks</td>
<td>negative</td>
</tr>
</tbody>
</table>

**Reproductive toxicity**

Not classified based on available information.

**Components:**

**Furosemide:**

Effects on fertility:
- Test Type: One-generation reproduction toxicity study
- Species: Rat
- Application Route: Ingestion
- General Toxicity - Parent: NOAEL: 90 mg/kg body weight
- Result: No effects on reproduction parameters

Effects on foetal development:
- Test Type: Fertility/early embryonic development
- Species: Rat
- Application Route: Ingestion
- General Toxicity Maternal: LOAEL: 50 mg/kg body weight
- Developmental Toxicity: NOAEL: 300 mg/kg body weight
- Result: No embryotoxic effects, No teratogenic effects

- Test Type: Fertility/early embryonic development
- Species: Mouse
- Application Route: Ingestion
- General Toxicity Maternal: LOAEL: 25 mg/kg body weight
- Result: Maternal toxicity observed., Fetal effects

- Test Type: Fertility/early embryonic development
- Species: Rabbit
- Application Route: Ingestion
- General Toxicity Maternal: LOAEL: <= 12 mg/kg body weight
- Developmental Toxicity: LOAEL: 12.5 mg/kg body weight
- Result: Maternal toxicity observed., Reduced number of viable fetuses
**SAFETY DATA SHEET**

**Furosemide Solid Formulation**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.7</td>
<td>10.10.2020</td>
<td>645631-00010</td>
<td>23.03.2020</td>
<td>03.05.2016</td>
</tr>
</tbody>
</table>

Test Type: Fertility/early embryonic development  
Species: Rabbit  
Application Route: Ingestion  
General Toxicity Maternal: LOAEL: 15 mg/kg body weight  
Result: Maternal toxicity observed., No effects on foetal development

**Cellulose:**

Effects on fertility : Test Type: One-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Result: negative

Effects on foetal development : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Ingestion  
Result: negative

**STOT - single exposure**

Not classified based on available information.

**STOT - repeated exposure**

Causes damage to organs (Kidney, Liver) through prolonged or repeated exposure.

**Components:**

**Furosemide:**

Exposure routes : Ingestion  
Target Organs : Kidney  
Assessment : Shown to produce significant health effects in animals at concentrations of 10 mg/kg bw or less.

**Repeated dose toxicity**

**Components:**

**Starch:**

Species : Rat  
NOAEL : >= 2,000 mg/kg  
Application Route : Skin contact  
Exposure time : 28 Days  
Method : OECD Test Guideline 410

**Furosemide:**

Species : Dog  
NOAEL : 4 mg/kg  
LOAEL : 8 mg/kg  
Application Route : Ingestion  
Exposure time : 12 Months  
Target Organs : Kidney  
Symptoms : Blood disorders  
Remarks : Significant toxicity observed in testing
Cellulose:
Species: Rat
NOAEL: >= 9,000 mg/kg
Application Route: Ingestion
Exposure time: 90 Days

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:
Furosemide:
Inhalation: Remarks: May be harmful if inhaled.
Skin contact: Remarks: May irritate skin.
Eye contact: Remarks: May cause eye irritation.
Ingestion: Symptoms: Kidney disorders, Headache, electrolyte imbalance, dry mouth, hearing loss, Irregular cardiac activity, Gastrointestinal disturbance, hypotension

Section 12: Ecological information

Ecotoxicity

Components:
Furosemide:
Toxicity to fish: LC50: 500 mg/l
Exposure time: 96 h

Cellulose:
Toxicity to fish: LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l
Exposure time: 48 h
Remarks: Based on data from similar materials

Persistence and degradability

Components:
Cellulose:
Biodegradability: Result: Readily biodegradable.

Bioaccumulative potential

Components:
Furosemide:
Partition coefficient: n-octanol/water: log Pow: 2.03

Mobility in soil
No data available
Other adverse effects
No data available

Section 13: Disposal considerations

Disposal methods
Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

Section 14: Transport information

International Regulations

UNRTDG
Not regulated as a dangerous good

IATA-DGR
Not regulated as a dangerous good

IMDG-Code
Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

National Regulations

NZS 5433
Not regulated as a dangerous good

Section 15: Regulatory information

Safety, health and environmental regulations/legislation specific for the substance or mixture

HSNO Approval Number
HSR100759 Veterinary Medicines Non dispersive Open System Application Group Standard 2017

HSW Controls
Certified handler certificate not required.
Tracking hazardous substance not required.
Refer to the Health and Safety at Work (Hazardous Substances) Regulations 2017, for further information.

The components of this product are reported in the following inventories:
AICS : not determined
DSL : not determined
IECSC : not determined
SAFETY DATA SHEET

Furosemide Solid Formulation

Version 2.7
Revision Date: 10.10.2020
SDS Number: 645631-00010
Date of last issue: 23.03.2020
Date of first issue: 03.05.2016

Section 16: Other information

Further information

Date format: dd.mm.yyyy

Full text of other abbreviations
ACGIH: USA. ACGIH Threshold Limit Values (TLV)
NZ OEL: New Zealand. Workplace Exposure Standards for Atmospheric Contaminants
ACGIH / TWA: 8-hour, time-weighted average
NZ OEL / WES-TWA: Workplace Exposure Standard - Time Weighted average

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text.
Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

NZ / EN